-
Mercati
athexgroup.grAthens Exchange GroupLeggi tuttoTogether for a unified, stronger European capital market.
-
Azioni
Sustainable finance2025 Euronext ESG Trends ReportLeggi tuttoA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indici
Access the white paperInvesting in the future of Europe with innovative indicesLeggi tuttoThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF
The European market place for ETFsEuronext ETF EuropeLeggi tuttoInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fondi
-
Obbligazioni
European Defence BondsGroupe BPCE lists the first bondLeggi tuttoFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Prodotti strutturati
-
Derivati
Where European Government Bonds Meet the FutureTrade Mini Bond FuturesLeggi tuttoTrade mini bond futures on main European government bonds
-
Commodities
- Panoramica
- Agricultural quotes
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Dairy derivatives
- Salmon derivatives
- Container Freight Futures
- Consegna e liquidazione
- Specifiche e disposizioni
- Commitments of Traders (CoT) report
- Commodity brokers
Take control of unpredictable dairy pricesEuropean Dairy DerivativesLeggi tuttoFutures and options on butter and skimmed milk powder now trading.
-
Documenti e risorse
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLeggi tuttoJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Novo to pay up to $2.6 billion to China's Hengrui for rights to weight-loss pill
By Andrew Silver and Patrick Wingrove
Sept 29 (Reuters) - Novo Nordisk will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals for the rights to an experimental weight-loss pill, expanding its pipeline through a second GLP-1 treatment deal with a Chinese partner.
The deal helps Novo shore up its competitive position against rivals such as Eli Lilly, with several patents set to expire in the next decade.
Its shares have tumbled more than 70% from record highs in the face of Lilly's competition, Reuters reported this month.
The deal also highlights the rapid rise of China's GLP-1 drug development industry, seeking to grab a bigger share of a booming market that analysts estimate will generate annual sales of about $100 billion globally in the next decade.
ELIGIBLE FOR TOTAL PAYMENTS OF UP TO $2.6 BILLION
The Novo deal makes Hengrui eligible for development-, regulatory- and commercial-related milestone payments of up to $2.3 billion, in addition to $300 million upfront, the Chinese drugmaker told the Hong Kong stock exchange in Tuesday's filing.
Novo will gain development, manufacturing and commercialisation rights to HRS-1596 outside Taiwan, Macao, Hong Kong and mainland China.
Markus Manns, a portfolio manager at Union Investment, told Reuters the deal was a positive for Novo, but the drugmaker needs to make larger deals with more advanced compounds to change market perception since its shares sank after losing share to rivals.
BMO Capital Markets analyst Evan Seigerman said in a note that the transaction is unlikely to shake up near-term competition, but said the candidate could serve as an attractive longer-term pipeline option for the Danish drugmaker.
Shares of Hengrui were up about 2% in Hong Kong after the news.
Hengrui's HRS-1596 is approved in China to initiate Phase I clinical trials for weight management and type 2 diabetes.
NEARLY 250 CHINESE GLP-1 DRUGS BEING DEVELOPED
Nearly 250 Chinese GLP-1 candidates are under development, says data provider Pharmcube, and major global drugmakers including AstraZeneca, Merck and Pfizer have struck rights deals with Chinese developers.
A trial of the jointly developed UBT251 obesity drug candidate of Novo and United Laboratories International showed a mean weight loss of up to 19.7% after 24 weeks.
Novo is preparing for a market in which pills play a much larger role, its Chief Executive Mike Doustdar told Reuters this month.
Existing products include Novo's once-daily pill Wegovy and Lilly's once-daily Foundayo, also in the GLP-1 class of drugs that mimic a gut hormone to curb appetite and regulate blood sugar in patients with diabetes.
POTENTIAL FOR REDUCED DOSAGE
In a statement, Novo said HRS-1596 had potential for development as an oral drug administered once a week, which would "substantially reduce dosing frequency and improve convenience compared with current offerings."
A Novo spokesperson also told Reuters it would plan global trials with the asset, but declined to provide timelines.
Lilly did not immediately respond to a request for comment on whether it had licensed GLP-1 assets from China.
(Reporting by Andrew Silver in Shanghai; Additional reporting by Shivangi Lahiri in Bengaluru and Patrick Wingrove in London; Editing by Harikrishnan Nair, Muralikumar Anantharaman, Clarence Fernandez and Louise Heavens)
Find it fast
Looking for more insights? Explore our other news sections for updates on sustainable finance, companies and financial education